|
Title
|
|
|
|
Inflammatory biomarkers in Alzheimer's disease plasma
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Introduction Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Methods A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Alzheimer's & dementia / Alzheimer’s Association [Chicago, Ill.] - Orlando, Fla, 2005, currens
| |
|
Publication
|
|
|
|
Orlando, Fla
:
Elsevier
,
2019
| |
|
ISSN
|
|
|
|
1552-5260
[print]
1552-5279
[online]
| |
|
DOI
|
|
|
|
10.1016/J.JALZ.2019.03.007
| |
|
Volume/pages
|
|
|
|
15
:6
(2019)
, p. 776-787
| |
|
ISI
|
|
|
|
000470084500005
| |
|
Pubmed ID
|
|
|
|
31047856
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|